Sugi Predict

Sugi Predict / Compounds / SCHEMBL415055

SCHEMBL415055

SCHEMBL415055

Cc1ccc(S(=O)(=O)OC(C)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA5A P35218 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ CA12 O43570 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA5B Q9Y2D0 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ VDR P11473 1/20 0.42
▸ TLR9 Q9NR96 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472888 0.86 GAA (0.48) GAACA1CA2CA5ACA9
SCHEMBL29367126 0.83 GAA (0.50) GAACA1CA2CA5ACA9
SCHEMBL777187 0.83 GAA (0.50) GAACA1CA2CA5ACA9
SCHEMBL4133598 0.82 GAA (0.45) GAACA1CA2CA5ACA9
SCHEMBL4124863 0.82 GAA (0.45) GAACA1CA2CA5ACA9
SCHEMBL28053836 0.82 GAA (0.48) GAACA1CA2CA5ACA9
Water SCHEMBL10687817 0.82 GAA (0.48) GAACA1CA2CA5ACA9
SCHEMBL22263347 0.80 CA1 (0.48) GAACA1CA2CA5ACA9
Hydrazine SCHEMBL10770191 0.80 CA1 (0.48) GAACA1CA2CA5ACA9
SCHEMBL1414702 0.79 GAA (0.42) GAACA1CA2CA5ACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023247596-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2023-12-28 — — WO disclosed
CN-114956954-A Preparation method of 1,1-difluoro-2-iodoethane 扬州市普林斯医药科技有限公司 2022-08-30 — — CN disclosed
US-10710968-B2 Radiolabeled erlotinib analogs and uses thereof HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2020-07-14 — — US disclosed
US-10561748-B2 Anthranilic acid derivatives MAHESHWARI DIVYA (IN) 2020-02-18 — — US disclosed
US-20190023664-A1 RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2019-01-24 — — US disclosed
EP-3402536-A1 RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED (IL) 2018-11-21 — — EP disclosed
US-20170281805-A1 NOVEL ANTHRANILIC ACID DERIVATIVES MAHESHWARI DIVYA (IN) 2017-10-05 — — US disclosed
WO-2017122205-A1 RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2017-07-20 — — WO disclosed
EP-2411362-B1 Tricyclic indole derivatives as PBR ligands GE HEALTHCARE LTD (GB) 2017-05-31 — — EP disclosed
US-9481685-B2 Imaging neuroinflammation GE HEALTHCARE LIMITED (GB) 2016-11-01 — — US disclosed
US-8790619-B2 Indole derivatives GE HEALTHCARE LIMITED (GB) 2014-07-29 — — US disclosed
US-8222407-B2 Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-07-17 — — US disclosed
EP-2411362-A2 INDOLE DERIVATIVES GE Healthcare UK Limited (GB) 2012-02-01 — — EP disclosed
US-20120020884-A1 INDOLE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2012-01-26 — — US disclosed
US-20110190618-A1 IMAGING NEUROINFLAMMATION GE HEALTHCARE LIMITED (GB) 2011-08-04 — — US disclosed
EP-2346880-A2 INDOLE DERIVATIVES SUITABLE FOR IMAGING NEUROINFLAMMATION GE Healthcare Limited (GB) 2011-07-27 — — EP disclosed
WO-2010109007-A2 INDOLE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2010-09-30 — — WO disclosed
US-20100197909-A1 MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-08-05 — — US disclosed
WO-2010037851-A2 IMAGING NEUROINFLAMMATION GE HEALTHCARE LIMITED (GB) 2010-04-08 — — WO disclosed
EP-2149571-A1 MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBSTITUENT AT 14-POSITION Kyorin Pharmaceutical Co., Ltd. (JP) 2010-02-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120020884-A1 INDOLE DERIVATIVES IDO1, IDO2, INMT GAA 4119/4885CA1 1815/4885CA2 2661/4885
US-20170281805-A1 NOVEL ANTHRANILIC ACID DERIVATIVES SLC47A1, ABCC1, ABCB1 GAA 338/4885CA1 522/4885CA2 1750/4885
US-10710968-B2 Radiolabeled erlotinib analogs and uses thereof EGFR, KRAS, ERBB4 GAA 1038/4885CA1 4150/4885CA2 4805/4885
US-20110190618-A1 IMAGING NEUROINFLAMMATION CX3CR1, CNR2, TSPO GAA 4821/4885CA1 2010/4885CA2 3093/4885
US-10561748-B2 Anthranilic acid derivatives SLC47A1, ABCC1, ABCB1 GAA 307/4885CA1 306/4885CA2 1281/4885
US-20190023664-A1 RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF EGFR, KRAS, ERBB4 GAA 1038/4885CA1 4150/4885CA2 4805/4885
US-20100197909-A1 MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION PELP1, MLN, SND1 GAA 420/4885CA1 4602/4885CA2 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.